A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 4, 2011, Pages 965-969

  Chen, Chun Hsin ^a,b   Lin, Tsang Yaw ^c   Chen, Tzu Ting ^d   Chen, Vincent Chin Hung ^e   Lin, Ni Chi ^c   Shao, Wen Chuan ^c   Lu, Mong Liang ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c Tsaotun Psychiatric Center   (Taiwan)

^d YULI VETERANS HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Insulin resistance; Insulin secretion; Metabolic syndrome; Quetiapine; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CHOLESTEROL; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; INSULIN; QUETIAPINE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OPEN STUDY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 79956051087     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.01.015     Document Type: Article

References (37)

1. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diab Care 2004, 27:596-601. American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, North American Association for the Study of ObesityNorth American Association for the Study of Obesity.
2. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004, 65:267-272. American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, North American Association for the Study of ObesityNorth American Association for the Study of Obesity.
3. Bergman R.N., Finegood D.G., Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985, 6:45-86.
4. Chiu C.C., Chen K.P., Liu H.C., Lu M.L. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006, 26:504-507.
5. Chiu C.C., Chen C.H., Chen B.Y., Yu S.H., Lu M.L. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:866-870.
6. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., Moller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424.
7. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diab Care 1991, 14:173-194.
8. Duijnhoven E.M., Boots J.M., Christiaans M.H., Wolffenbuttel B.H., Van Hooff J.P. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001, 12:583-588.
9. Dwyer D.S., Lu X.H., Bradley R.J. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res 2003, 971:31-39.
10. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
11. Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology 1976, 217-222. National Institute of Mental Health, Rockville, MD, Revised (DHEW Publ No ADM 76-338).
12. Haupt D.W., Fahnestock P.A., Flavin K.A., Schweiger J.A., Stevens A., Hessler M.J., et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007, 32:2561-2569.
13. Henderson D.C. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?. CNS Drugs 2002, 16:77-89.
14. Henderson D.C., Copeland P.M., Borba C.P., Daley T.B., Nguyen D.D., Cagliero E., et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006, 67:789-797.
15. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007, 32:289-297.
16. Huang M.C., Lu M.L., Tsai C.J., Chen P.Y., Chiu C.C., Jian D.L., et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009, 120:274-280.
17. Hwang L.C., Bai C.H., Chen C.J. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006, 105:626-635.
18. Lehtovirta M., Kaprio J., Groop L., Trombetta M., Bonadonna R.C. Heritability of model-derived parameters of beta cell secretion during intravenous and oral glucose tolerance tests: a study of twins. Diabetologia 2005, 48:1604-1613.
19. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
20. Liebzeit K.A., Markowitz J.S., Caley C.F. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001, 11:25-32.
21. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987, 334:1-100.
22. Mahendran R., Hendricks M., Chan Y.H. Weight gain in Asian patients on second-generation antipsychotics. Ann Acad Med Singapore 2010, 39:118-121.
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
24. Melkersson K., Jansson E. The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro. Neuro Endocrinol Lett 2005, 26:205-208.
25. Meyer J.M. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001, 62(Suppl. 27):27-34. discussion 40-1.
26. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
27. Newcomer J.W., Ratner R.E., Eriksson J.W., Emsley R., Meulien D., Miller F., et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009, 70:487-499.
28. Oriot P., Feys J.L., Mertens de Wilmars S., Misson A., Ayache L., Fagnart O., et al. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab 2008, 34:490-496.
29. Patel J.K., Buckley P.F., Woolson S., Hamer R.M., McEvoy J.P., Perkins D.O., et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009, 111:9-16.
30. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 2010, 125:169-179.
31. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010, 123:225-233.
32. Smith G.C., Chaussade C., Vickers M., Jensen J., Shepherd P.R. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 2008, 51:2309-2317.
33. Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008, 192:406-411.
34. Tan C.E., Ma S., Wai D., Chew S.K., Tai E.S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diab Care 2004, 27:1182-1186.
35. Tanne J.H. AstraZeneca to pay $198m to patients over diabetes claims. BMJ 2010, 341:c4422.
36. van Winkel R., De Hert M., Wampers M., Van Eyck D., Hanssens L., Scheen A., et al. Major changes in glucose metabolism, including new-onset diabetes, within 3months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008, 69:472-479.
37. Wilson D.R., D'Souza L., Sarkar N., Newton M., Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003, 59:1-6.